Study results have revealed that ferumoxytol may be a suitable treatment alternative to iron sucrose for patients with iron deficiency anaemia when oral iron is unsatisfactory or intolerable. The authors also suggest that ferumoxytol has the potential to increase treatment compliance in this patient population.
The phase III, open-label, non-inferiority study randomised 605 patients to receive ferumoxytol (n=406, two 510 mg doses [5 ± 3 days apart]) or iron sucrose (n=199, five 200 mg doses [5 non-consecutive days over 14 days]) for five weeks. Ferumoxytol was shown to be non-inferior to iron sucrose. Eighty-four percent of ferumoxytol treated patients had a haemoglobin increase of ≥2 g/dL at any time from Baseline to Week 5 compared with 81.4% of patients treated with iron sucrose (non-inferiority margin –15%). Additionally, ferumoxytol was superior to iron sucrose (2.7 vs 2.4 g/dL; p=0.0124) for mean change in haemoglobin from baseline to Week 5. Change in transferrin saturation, quality-of-life, and safety were similar between the two groups.
Ferumoxytol can be administered as a rapid, high-dose, intravenous injection, which does not require a test dose prior to administration. These features result in fewer administrations being required compared with several other intravenous iron therapies. The authors suggest that ferumoxytol has the potential to improve treatment compliance in patients with iron deficiency anaemia.
The authors conclude that ferumoxytol may extend beyond its current indication for the treatment of iron deficiency anaemia in patients with chronic kidney disease to a broader population of patients.
The full article is available in the March 2014 issue of the American Journal of Hematology. For information on the treatment of iron deficiency, please click here.